Free tool
FAERS Monitor: Sklice
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202736 or its brand name (Sklice, Ivermectin). Reports on generic versions are filed under their own applications.
Reports
3,499
Serious
1,942
56% of reports
Hospitalization
991
Death reported
329
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective644
- off label use403
- product use in unapproved indication286
- pruritus172
- headache165
- fatigue125
- asthenia121
- nausea115
- pyrexia113
- diarrhoea102
- strongyloidiasis102
- vomiting102
- rash94
- pain93
- dyspnoea90
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 6 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 7 |
| 2009 | 12 |
| 2010 | 3 |
| 2011 | 11 |
| 2012 | 6 |
| 2013 | 61 |
| 2014 | 65 |
| 2015 | 60 |
| 2016 | 47 |
| 2017 | 212 |
| 2018 | 269 |
| 2019 | 219 |
| 2020 | 201 |
| 2021 | 387 |
| 2022 | 350 |
| 2023 | 295 |
| 2024 | 326 |
| 2025 | 525 |
| 2026 | 431 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,660 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| strongyloidiasisSignal | 102 | 405.1 | 332.4 | 38,143 |
| product use in unapproved indicationSignal | 286 | 6.9 | 6.2 | 1,465 |
| drug ineffectiveSignal | 644 | 2.9 | 2.7 | 876 |
| off label useSignal | 403 | 2.8 | 2.5 | 473 |
| pruritusSignal | 172 | 2.7 | 2.3 | 184 |
| pyrexia | 113 | 2.0 | 1.6 | 53 |
| asthenia | 121 | 1.9 | 1.6 | 55 |
| headache | 165 | 1.6 | 1.4 | 36 |
| vomiting | 102 | 1.3 | 1.1 | 7 |
| rash | 94 | 1.3 | 1.1 | 6 |
| fatigue | 125 | 1.0 | 0.8 | 0 |
| dyspnoea | 90 | 1.0 | 0.8 | 0 |
| diarrhoea | 102 | 0.9 | 0.8 | 0 |
| pain | 93 | 0.9 | 0.7 | 1 |
| nausea | 115 | 0.9 | 0.7 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.